Senolytic CAR-T Cells: How Cancer Immunotherapy Is Being Reengineered to Clear Aging Cells

For nearly a decade, the dream of clearing “zombie cells” from aging human bodies rested on two oral drugs that were never designed for the job. Dasatinib, a tyrosine kinase inhibitor approved for leukemia, and quercetin, a plant flavonoid sold in supplement aisles, became the first senolytics to enter human clinical trials. Their results, presented most recently in a 2025 Phase 2 Mayo Clinic trial in postmenopausal women and a small eBioMedicine pilot in adults at risk for Alzheimer’s disease, have been described honestly by the principal investigators as “subtle.” In the bones of older women, senolytic therapy nudged a few biomarkers in the right direction but failed to separate from placebo on the outcomes that matter most. In the cognitive study, twelve volunteers showed inflammatory markers trending in the right direction, but the trial was too small to prove anything.

Presented By Our Partners

If that were the whole story, cellular senescence would be filed away as another elegant idea from mouse biology that did not translate to human longevity. But that is not the whole story. While oral senolytics were working through their cautious clinical chapter, a parallel program was quietly advancing through the laboratories of Memorial Sloan Kettering Cancer Center and Cold Spring Harbor Laboratory. That program borrowed the most successful cancer immunotherapy of the past decade, chimeric antigen receptor T cell therapy, and retrained it to hunt something other than tumors. It was retrained to hunt aging cells. And in January 2026, the first reports of its effects on intestinal regeneration, glucose control, and exercise capacity in aged animals suggest that the real senolytic revolution may still be ahead of us.

What Cellular Senescence Actually Is

Cellular senescence is one of the most counterintuitive features of mammalian biology. When a cell experiences damage that it cannot repair, whether from telomere attrition, oxidative stress, oncogene activation, or radiation, it has two options. It can die by apoptosis, or it can stop dividing permanently and remain in a state of arrested metabolism. The arrested state is called senescence, and it evolved as a tumor suppression mechanism. A cell that can no longer divide cannot become a cancer.

The problem is that senescent cells do not simply sit quietly. They acquire what biologists call a senescence-associated secretory phenotype, usually abbreviated SASP, a cocktail of inflammatory cytokines, chemokines, proteases, and growth factors that remodel the surrounding tissue. In small numbers and for short periods, SASP signaling is actually useful. It attracts immune cells that clear damaged tissue, it helps wound healing, and it plays a constructive role in embryonic development. The trouble begins when senescent cells accumulate faster than the immune system can clear them, which is precisely what happens with age.

By the seventh or eighth decade of human life, senescent cells are measurably enriched in adipose tissue, skeletal muscle, the pancreas, the brain, the cardiovascular system, the kidneys, the lungs, and the intestinal lining. They drive chronic low-grade inflammation, sometimes called “inflammaging,” that mediates many of the diseases commonly attributed to aging itself. Mouse experiments have shown, repeatedly and dramatically, that genetically forcing the clearance of senescent cells extends healthspan, preserves organ function, improves cognition, and modestly extends lifespan. The question that has dominated the field for a decade is how to replicate that effect pharmacologically in humans, without genetic engineering of the patient.

The First Generation: Dasatinib Plus Quercetin and Its Disappointments

The dasatinib plus quercetin combination, often written as D+Q, emerged from a 2015 screen at Mayo Clinic identifying compounds that could selectively kill senescent cells in culture. The logic was that senescent cells upregulate anti-apoptotic pathways to resist their own death, and drugs that transiently block those pathways should tip senescent cells, but not healthy cells, into apoptosis. In 2019, James Kirkland and colleagues at Mayo published in EBioMedicine the first open-label pilot showing that a three-day course of D+Q reduced p16INK4A-positive cells in abdominal subcutaneous adipose biopsies in nine patients with diabetic kidney disease. That finding, that a senolytic could measurably reduce senescent cell burden in human tissue, was the opening volley of the field.

The trials that followed have been more sobering. In 2025, Mayo Clinic investigators reported results from a 20-week Phase 2 randomized trial of D+Q in sixty postmenopausal women aged 62 to 88, published in Nature Medicine. The primary outcomes were markers of bone formation and resorption. At early timepoints, bone formation markers trended higher in the senolytic group, but by the 20-week endpoint, the two groups were indistinguishable. The National Institute on Aging summarized the finding this way: senolytics produced a subtle effect, despite earlier promising evidence from mouse studies.

A separate 2025 pilot, published in eBioMedicine by investigators at the University of Texas Health Science Center at San Antonio, tested intermittent D+Q in twelve older adults with mild cognitive impairment at risk for Alzheimer’s disease. Over 12 weeks, the therapy was safe, produced no serious adverse events, and reduced one inflammatory marker that correlated with memory performance. But twelve participants cannot prove efficacy, and the authors explicitly framed the work as a feasibility study to justify larger trials.

The honest interpretation of the D+Q data so far is that oral senolytics can reduce senescent cell burden in humans, but the reductions appear modest, the downstream clinical effects are harder to detect, and the drugs are not selective enough to drive unambiguous benefit. Part of the problem is pharmacology. Dasatinib hits dozens of kinases, quercetin has a short half-life and poor bioavailability, and neither was optimized for selective senolytic action. Part of the problem is biology. Senescent cells are not a single uniform population. They differ by tissue, by the original stressor, by their age, and by their secretory profile. A drug that works on one subset may leave others untouched.

Enter CAR-T cells.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Borrowing the Cancer Playbook

Chimeric antigen receptor T cell therapy was developed in the 2000s and 2010s as a treatment for B cell leukemias and lymphomas. The engineering principle is elegant. A patient’s own T cells are collected by apheresis, genetically modified to express a synthetic receptor that recognizes a specific surface protein, expanded in culture, and infused back into the patient. Once in circulation, the engineered T cells seek out and destroy any cell displaying the target protein. Six CAR-T products are now approved by the FDA, and the technology has produced durable remissions in patients who had failed every other treatment.

The question that Corina Amor Vegas, then a postdoctoral fellow in Scott Lowe’s laboratory at MSK, asked in the late 2010s was whether a CAR-T cell could be programmed to recognize a senescent cell the way it recognizes a leukemic cell. The answer required identifying a surface marker that is reliably upregulated on senescent cells across tissues, yet spared on healthy cells. After screening candidate proteins, Amor and colleagues converged on urokinase plasminogen activator receptor, a cell surface molecule better known as uPAR, or PLAUR. In their foundational paper, published in Nature in 2020, the team showed that uPAR is highly expressed on senescent cells induced by multiple stressors, that anti-uPAR CAR-T cells could selectively eliminate senescent cells in culture and in mouse models of liver fibrosis, and that the therapy improved tissue function without evident toxicity.

That paper was important, but it was a proof of concept. The more consequential follow-up came in March 2024, when Amor, now leading her own lab at Cold Spring Harbor, published a paper in Nature Aging titled “Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction.” In that study, a single infusion of anti-uPAR CAR-T cells into young adult mice persisted in the spleen and liver for 12 months, selectively eliminated uPAR-positive senescent cells as they arose over time, improved glucose tolerance in aged animals, reduced systemic inflammation, and increased treadmill exercise capacity compared to controls. Mice treated preventively at three months of age, roughly the young adult equivalent in human terms, still showed metabolic and functional advantages deep into old age.

The implications were striking. A single cell therapy, delivered once, provided durable senolytic surveillance for the lifetime of the animal. Unlike oral drugs, which must be redosed repeatedly and clear from circulation within hours, a population of engineered T cells can expand when they encounter their target and contract when they do not. In principle, they function as a living, self-renewing senolytic.

The January 2026 Gut Breakthrough

The most recent data, reported in late 2025 and early 2026, extend the approach into an organ that dominates human longevity in ways that are only beginning to be appreciated: the intestine. Researchers using anti-uPAR CAR-T cells in aging mice demonstrated that clearing senescent cells from the intestinal lining accelerated regeneration of the gut epithelium, reduced mucosal inflammation, and improved nutrient absorption. Striking protective effects were observed against radiation-induced intestinal injury, with the benefit persisting for up to a year after a single infusion. Early results in human intestinal organoids suggest the same approach could be translatable to patients with age-related gut decline and to cancer patients recovering from abdominal radiation therapy.

Why does this matter beyond the mouse gut? Because the intestinal epithelium is the fastest turning over tissue in the body, it is one of the first organs to show functional decline with age, and it sits at the interface of three pillars of longevity biology: the microbiome, systemic inflammation, and nutrient sensing. A therapy that restores intestinal regeneration would, at least in principle, improve all three at once.

Complementary work from the MSK team has shown that uPAR-positive cells are also a feature of certain tumor microenvironments. A 2026 Cell paper described a “convergent uPAR-positive tumor ecosystem” that creates broad vulnerability to CAR-T therapy across tumor types. That finding is likely to accelerate the clinical translation of anti-uPAR CAR-T cells, because the regulatory path is clearer for a cancer indication than for an aging indication, and successful cancer trials will generate the safety data needed to justify studies in age-related disease.

Why This Is Harder Than It Sounds

For all the excitement, senolytic CAR-T therapy faces three hard problems that will determine whether it ever reaches the clinic as a longevity intervention.

The first is target specificity. uPAR is enriched on senescent cells, but it is not exclusive to them. It is expressed on activated immune cells, on some healthy epithelial populations, and on tumor cells. Off-target clearance, especially in patients who do not have cancer, raises the safety bar considerably. Researchers are developing second-generation constructs with logic gates that require two senescence-associated markers to be present simultaneously before the CAR-T cell acts, and with inducible “kill switches” that allow the engineered cells to be shut down if adverse effects emerge.

The second is immunosenescence. The immune system itself ages. By the seventh decade, the T cell repertoire contracts, thymic output dwindles, and the cells that would be harvested for CAR-T engineering from an elderly patient are often exhausted or dysfunctional before they ever see the lab. One proposed solution is allogeneic CAR-T therapy, in which the engineered cells come from a healthy younger donor rather than from the patient. This approach has shown promise in oncology and could, in principle, deliver a more competent population of senolytic CAR-T cells to aged recipients.

The third is cost and logistics. Current autologous CAR-T therapies cost between $373,000 and $475,000 per infusion before the hospitalization, monitoring, and cytokine release syndrome management that typically accompany treatment. A therapy priced that way cannot scale as a preventive intervention for healthy aging. Off-the-shelf allogeneic products, in vivo CAR delivery using lipid nanoparticles to engineer T cells inside the patient, and non-viral manufacturing platforms are all active engineering fronts that could, over the next several years, drop the price by an order of magnitude.

What 2026 Looks Like From Here

The clinical translation timeline for senolytic CAR-T is becoming clearer. The first human trials will almost certainly come through oncology indications where senescent cells contribute to disease biology, such as radiation-induced fibrosis, cancer-associated cachexia, or therapy-related accelerated aging in bone marrow transplant survivors. A Phase 1 trial for senolytic CAR-T in secondary progressive multiple sclerosis has been registered as NCT07270120, reflecting the recognition that neurological conditions driven by senescent glial cells may be unusually accessible targets. Preclinical programs in pulmonary fibrosis, osteoarthritis, and diabetic kidney disease are advancing toward IND-enabling studies.

In parallel, the mitochondrial transplantation field is approaching its own first human trials for age-related indications, with one research team targeting 2026 for the first infusions into elderly patients experiencing mitochondrial dysfunction. Taken together, the cellular health pillar of longevity medicine is undergoing the same kind of shift that cancer therapy went through in the 2010s. The question is no longer whether cells can be targeted for therapeutic purposes. It is which cells, with what precision, and at what cost.

What This Means For You

Senolytic CAR-T therapy is not available outside of research settings, and the first human trials for aging-related indications are years from delivering definitive results. For most readers of Healthcare Discovery, that means the practical question is not whether to pursue an experimental therapy, but how to reduce your senescent cell burden now with the tools that are already in hand.

The interventions with the strongest evidence for lowering senescent cell accumulation are, reassuringly, the same interventions that drive every other longevity outcome. Regular resistance training and moderate aerobic exercise reduce markers of cellular senescence in skeletal muscle and adipose tissue, as multiple human studies have now shown. Caloric sufficiency without chronic overnutrition keeps senescent cell accumulation lower in fat depots, where age-related senescence is most pronounced. Sleep of adequate duration and quality supports the immune surveillance that clears senescent cells naturally. And avoiding chronic exposure to DNA damaging stressors, from ultraviolet radiation to tobacco to excessive alcohol, reduces the rate at which new senescent cells are generated in the first place.

If you are considering oral senolytics such as fisetin, quercetin, or off-label dasatinib plus quercetin, approach them with the humility the data deserve. The human evidence shows modest effects at best, the dosing schedules are not standardized, and dasatinib in particular carries a meaningful side effect profile even in short courses. If you do decide to pursue senolytic supplementation, do so in consultation with a physician who is familiar with the trial literature, and do not expect the dramatic results seen in mouse models.

Most importantly, think about cellular senescence as one layer in a multilayered longevity framework. Clearing senescent cells is valuable precisely because it reduces inflammation, preserves stem cell niches, and supports tissue regeneration. But the same goals can be advanced through interventions on the mitochondrial pillar, the metabolic pillar, the microbiome pillar, and the sleep pillar. A coherent longevity strategy works on several layers at once, and the cellular senescence layer is one of the most responsive to basic lifestyle inputs.

The promise of senolytic CAR-T cells is that, within the next decade, there may finally be a precise, durable, clinically validated way to clear aging cells from the human body. The work to get there is being done right now, in laboratories in New York, Houston, Rochester, and beyond. When it arrives, the winners will be the patients who are already doing the fundamental work of preserving their immune systems, their metabolic health, and their tissue reserves, because those are the patients whose bodies will be ready to benefit.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.